GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

This study is testing whether adding a weekly injectable medication called tirzepatide (which targets hormones GIP and GLP-1, typically used for type 2 diabetes and weight loss) to an automated insulin delivery (AID) system can improve blood sugar control in adults with type 1 diabetes. **You may be eligible if...** - You have had type 1 diabetes for at least 12 months - You are between 18 and 65 years old - You have been using an automated insulin delivery system for at least 3 months - Your HbA1c (a measure of average blood sugar) is between 6.5% and 10% - Your BMI is 23 or above **You may NOT be eligible if...** - You have had diabetic ketoacidosis or a severe hypoglycemic episode (loss of consciousness or seizure) in the past 6 months - You are pregnant or breastfeeding, or planning to become pregnant - You have severe kidney disease, severe gastroparesis, or active pancreatitis - You have a personal or family history of medullary thyroid cancer or a condition called MEN-2 - You have had significant heart problems in the past 2 months Talk to your doctor to see if this trial is right for you.